1
|
Muthuramalingam SR, Braybrooke JP, Blann AD, Madhusudan S, Wilner S, Jenkins A, Han C, Kaur K, Perren T, Ganesan TS. A prospective randomised phase II trial of thalidomide with carboplatin compared with carboplatin alone as a first-line therapy in women with ovarian cancer, with evaluation of potential surrogate markers of angiogenesis. EUR J GYNAECOL ONCOL 2011; 32:253-258. [PMID: 21797111] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Abstract
OBJECTIVES To compare the safety and efficacy of thalidomide in combination with carboplatin to carboplatin alone as a first-line therapy in women with ovarian cancer and to evaluate the anti-angiogenic effects of thalidomide by measurement of surrogate markers of angiogenesis. METHODS Forty patients with Stage IC-IV ovarian cancer were randomly assigned to receive either carboplatin (AUC 7) intravenously every four weeks for up to six doses (n = 20) or carboplatin at the same dose and schedule, plus thalidomide 100 mg orally daily for six months (n = 20). RESULTS After median follow-up of 1.95 years, there was no difference in the overall response rate (90% in carboplatin arm, 75% in combination arm; p = 0.41). Increased incidence of symptoms of constipation, dizziness, tiredness and peripheral neuropathy was observed in the combination arm. There was a significant fall in CA-125 and E-selectin in both arms after treatment and VCAM-1 in the carboplatin arm. No significant difference between the two arms was observed in any of the markers analysed. CONCLUSIONS In our trial the addition of thalidomide to carboplatin was well tolerated with no increased efficacy. The fall in some of the angiogenic markers in both groups may reflect tumour response rather than any specific anti-angiogenic effect of thalidomide.
Collapse
Affiliation(s)
- S R Muthuramalingam
- Cancer Research UK Medical Oncology Unit, University of Oxford, Churchill Hospital, Oxford
| | | | | | | | | | | | | | | | | | | |
Collapse
|
2
|
Abstract
Prostate cancer is the second most common cancer in men in the UK, and the incidence of prostate cancer has increased dramatically over the past two decades. Although most men are diagnosed at early stage, more than 50% develop locally advanced or metastatic disease. Androgen ablation with luteinising hormone-releasing hormone (LHRH) agonists alone, or in combination with anti-androgens, is the standard treatment for men with metastatic prostate cancer. Unfortunately, almost all men develop progressive disease after a variable time period, despite the maximal androgen blockade. The management of hormone refractory prostate cancer (HRPC) is challenging, as there is no uniformly accepted strategy. Various treatment options, including second-line hormone therapy, are discussed. Chemotherapy is being increasingly used and, importantly, docetaxel and estramustine may play an important role in the near future. The role of radiotherapy, strontium-89, bisphosphonates, novel agents and future therapies are also outlined.
Collapse
Affiliation(s)
- S R Muthuramalingam
- Cancer Research UK Oncology Unit, Churchill Hospital, Headington, Oxford, UK
| | | | | |
Collapse
|
3
|
Muthuramalingam SR, Braybrooke J, Madhusudan S, Blann A, Wilner S, Jenkins A, Han C, Perren T, Ganesan TS. A randomised trial of carboplatin versus carboplatin and thalidomide in ovarian cancer, with evaluation of potential surrogate markers of angiogenesis. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.5024] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- S. R. Muthuramalingam
- CRUK Dept. of Medical Oncology, Churchill Hospital, Oxford, United Kingdom; Thrombosis and Vascular Biology Laboratory, Brimingham, United Kingdom; St. James Hospital, Leeds, United Kingdom
| | - J. Braybrooke
- CRUK Dept. of Medical Oncology, Churchill Hospital, Oxford, United Kingdom; Thrombosis and Vascular Biology Laboratory, Brimingham, United Kingdom; St. James Hospital, Leeds, United Kingdom
| | - S. Madhusudan
- CRUK Dept. of Medical Oncology, Churchill Hospital, Oxford, United Kingdom; Thrombosis and Vascular Biology Laboratory, Brimingham, United Kingdom; St. James Hospital, Leeds, United Kingdom
| | - A. Blann
- CRUK Dept. of Medical Oncology, Churchill Hospital, Oxford, United Kingdom; Thrombosis and Vascular Biology Laboratory, Brimingham, United Kingdom; St. James Hospital, Leeds, United Kingdom
| | - S. Wilner
- CRUK Dept. of Medical Oncology, Churchill Hospital, Oxford, United Kingdom; Thrombosis and Vascular Biology Laboratory, Brimingham, United Kingdom; St. James Hospital, Leeds, United Kingdom
| | - A. Jenkins
- CRUK Dept. of Medical Oncology, Churchill Hospital, Oxford, United Kingdom; Thrombosis and Vascular Biology Laboratory, Brimingham, United Kingdom; St. James Hospital, Leeds, United Kingdom
| | - C. Han
- CRUK Dept. of Medical Oncology, Churchill Hospital, Oxford, United Kingdom; Thrombosis and Vascular Biology Laboratory, Brimingham, United Kingdom; St. James Hospital, Leeds, United Kingdom
| | - T. Perren
- CRUK Dept. of Medical Oncology, Churchill Hospital, Oxford, United Kingdom; Thrombosis and Vascular Biology Laboratory, Brimingham, United Kingdom; St. James Hospital, Leeds, United Kingdom
| | - T. S. Ganesan
- CRUK Dept. of Medical Oncology, Churchill Hospital, Oxford, United Kingdom; Thrombosis and Vascular Biology Laboratory, Brimingham, United Kingdom; St. James Hospital, Leeds, United Kingdom
| |
Collapse
|